Could a daily powder boost skin elasticity and fight fatigue?
NCT ID NCT07703215
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study tests whether a daily supplement called NPQ Plus can improve skin health, antioxidant status, fatigue, and well-being in healthy adults with minor skin concerns like dryness or itchiness. The supplement contains polyphenols, NMN, PQQ, CoQ10, and minerals. Participants take one sachet daily for 12 weeks, and researchers measure skin elasticity, hydration, barrier function, and blood markers of oxidative stress.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a dietary supplement containing polyphenols, nicotinamide mononucleotide (NMN), pyrroloquinoline quinone (PQQ), coenzyme Q10 (CoQ10), and a trace mineral complex
- What this could lead to
- If it works, this could point toward a simple daily supplement that improves skin elasticity, hydration, and reduces fatigue in people with mild skin concerns.
- What could go wrong
- This is a small, early study with no placebo group, so results may be due to chance or the placebo effect. The supplement is not a treatment for eczema or other skin diseases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
55 people
The number who actually took part.
- Started
-
Jan 2026
- Finished
-
Apr 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Experiencing at least one skin concern (e.g., itchiness, dryness, roughness, flaking, or skin cracking) within the previous 3 months. * Willing and able to consume one sachet of NPQ Plus daily for 12 weeks. * Willing to attend all scheduled study visits and assessments. * Able to understand the study procedures and provide written informed consent. Exclusion Criteria: * Consumption of dietary supplements intended to improve skin health within the previous 3 months. * Pregnant or breastfeeding women. * Known allergy or hypersensitivity to any ingredient in NPQ Plus. * Presence of any medical condition or concurrent medication that, in the opinion of the investigator, could interfere with study participation or outcome assessments. * Participation in another clinical study within the previous 3 months. * Unable or unwilling to comply with the study protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Antioxidant capacity are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCSI University
Cheras, Kuala Lumpur, 56000, Malaysia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can a berry extract help athletes bounce back after brutal workouts?
- Can a smartwatch predict which cancer patients return to hospital?
- Can a Post-Training drink help young footballers recover and sleep better?
- Smart mask aims to measure blood oxygen through your face
- Skin scans may predict who responds to dupilumab for eczema